Cell Cycle Arrest and Apoptosis-Inducing Ability of Benzimidazole Derivatives: Design, Synthesis, Docking, and Biological Evaluation.
Syed NazreenAbdulraheem S A AlmalkiSerag Eldin I ElbehairiAli A ShatiMohammad Y AlfaifiAhmed A ElhenawyNawaf I AlsenaniAnas AlfarsiAbdulrahman AlhadhramiEsam A AlqurashiMohammad Mahboob AlamPublished in: Molecules (Basel, Switzerland) (2022)
In the current study, new benzimidazole-based 1,3,4-oxadiazole derivatives have been synthesized and characterized by NMR, IR, MS, and elemental analysis. The final compounds were screened for cytotoxicity against MDA-MB-231, SKOV3, and A549 cell lines and EGFR for inhibitory activities. Compounds 10 and 13 were found to be the most active against all the tested cell lines, comparable to doxorubicin, and exhibited significant inhibition on EGFR kinase, with IC 50 0.33 and 0.38 μM, respectively, comparable to erlotinib (IC 50 0.39 μM). Furthermore, these two compounds effectively suppressed cell cycle progression and induced cell apoptosis in MDA-MB-231, SKOV3, and A549 cell lines. The docking studies revealed that these compounds showed interactions similar to erlotinib at the EGFR site. It can be concluded that the synthesized molecules effectively inhibit EGFR, can arrest the cell cycle, and may trigger apoptosis and therefore, could be used as lead molecules in the development of new anticancer agents targeting EGFR kinase.
Keyphrases
- cell cycle
- cell cycle arrest
- epidermal growth factor receptor
- tyrosine kinase
- small cell lung cancer
- cell proliferation
- cell death
- pi k akt
- advanced non small cell lung cancer
- oxidative stress
- molecular dynamics
- endoplasmic reticulum stress
- molecular dynamics simulations
- signaling pathway
- cancer therapy
- high resolution
- multiple sclerosis
- high glucose
- protein protein
- small molecule
- single cell
- endothelial cells
- ms ms
- drug induced